WS
MRNS

Wedbush Securities’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Wedbush Securities’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,750
Closed -$14K – 873
2016
Q2 		$14K Buy
+2,750
New +$50.6K ﹤0.01% 773

Other funds holding MRNS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Wedbush Securities's MRNS Position: Q3 2016 in Review

Wedbush Securities sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2016, closing a stake of 2,750 shares — an estimated $14K sold.

Wedbush Securities first reported a position in MRNS in Q2 2016 and held it in 1 quarter. The position peaked at $14K in Q2 2016. 26 funds tracked by Wall St. Rank hold MRNS as of Q3 2016.

  • Wedbush Securities reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2016 after selling out during the quarter.
  • Wedbush Securities sold 2,750 Marinus Pharmaceuticals, Inc shares in Q3 2016, an estimated $14K.
  • Wedbush Securities first reported a position in Marinus Pharmaceuticals, Inc in Q2 2016 and held it in 1 quarter.
  • Wedbush Securities's Marinus Pharmaceuticals, Inc position peaked at $14K in Q2 2016.
  • 26 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2016.

Based on Wedbush Securities's 13F filing for Q3 2016, filed 4 Nov 2016.